Upcoming Events
  1. ALTG open MAC and SAC meetings

    November 20
  2. Virtual 2020 World Conference on Lung Cancer Singapore

    January 28, 2021 @ 8:00 am - January 31, 2021 @ 5:00 pm

Thoracic oncology highlights from ASCO2020 webinar- recording and evaluation survey

Please fill in the evaluation survey if you have not already done so by clicking on the survey icon at the base of your webinar console.

Please access the recording and evaluation survey here

ALTG awarded $12 million in funding

The ALTG is pleased to announce over $12 million in funding has been successfully awarded to ALTG, NHMRC Clinical Trial Centre and the Australian Genomic Cancer Medicine Centre for the ASPiRATION project. In this ground-breaking precision medicine study, led by ALTG President A/Prof Nick Pavlakis and ALTG Scientific Advisory Committee Chair, Prof Ben Solomon, ASPiRATION will explore the benefit of routine comprehensive genomic profiling in 1000 newly-diagnosed metastatic, non-squamous, NSCLC patients in Australia. The enhanced genomic profiling will assist in personalising patient care by matching patients to targeted treatments as early as possible to improve patient outcomes.

ALTG Portfolio

Ongoing trials

  • ALTG 14/001 BR.31: A phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer
  • ALTG 15/003 DREAM: A phase II trial of durvalumab with first line chemotherapy in mesothelioma with a safety run in
  • ALTG 14/002 NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer progressing after first or second line chemotherapy
  • ALTG 13/008 PEARL: Investigating the impact of early palliative care

Concepts in development – view details

  • ALTG 15/004 BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with high-risk advanced or metastatic (stage IIIB/IV) squamous or non-squamous NSCLC
  • ALTG 16/002 Fear of recurrence in patients with early stage NSCLC
  • ALTG 16/003 Optimal duration of treatment with immunotherapy (NSCLC)
  • ALTG 16/004 SCRIBE: A phase 2 study of nivolumab with radiotherapy or nivolumab with ipilimumab in the treatment of small cell lung cancer brain metastases
  • ALTG 16/005 OSCILLATE: Alternating Osimertinib and Gefitinib in patients with EGFR T790M positive NSCLC
  • ALTG 16/007 ALKTERNATE: Randomized Phase 2 study of fixed alternating crizotinib/lortatinib versus sequential crozotinib followed by lortalinib, as first line therapy in ALK gene rearranged NSCLC
  • ALTG 16/008 NINA: Phase 2 single arm study of nintedanib in combination with avelumab as second line therapy in patients with advanced lung adenocarcinoma
  • ALTG 16/009 A Phase 2 study of durvalumab plus tremelimumab in patients with relapsed EGFR mutant non-small cell lung cancer
  • ALTG 16/010 LungCare: A multicentre randomised controlled trial comparing primary care vs hospital-based follow-up following surgical lobectomy for NSCLC
  • ALTG 16/012 STIMULI: A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after chemo-radiotherapy
  • ALTG 17/001 Active surveillance in patients with Malignant Pleural Mesothelioma, a prospective single arm phase II trial

Endorsed trials – in development and ongoing

  • ALTG 16/013 Activities and influences of the specialist lung cancer nurse: a mixed-method comparative study of the multidisciplinary team assigned and not assigned a specialist lung cancer nurse
  • ALTG 16/011 CORE: Conventional care Or Radioablation for Extracranial metastases
  • ALTG 15/001 SABR-OS: A randomised phase II trial to test the feasibility of randomising patients with peripheral stage I non-small cell lung cancer to either Stereotactic Ablative Radiotherapy (SABR) Or Surgery
  • ALTG 13/004 OPAL: Online and Phone Assistance for Lung cancer
  • ALTG 13/003 Rekindle: testing an online resource to promote sexual wellbeing for both patients and their partners
  • ALTG 13/002 Health related quality of life in Malignant Mesothelioma
  • ALTG 13/001 TROG 13.01 SAFRON II: Stereotactic Ablative Fractionated Radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomised Phase II Trial
  • ALTG 10/001 PLUNG: Randomised phase III trial of high dose palliative radiotherapy (HDPRT) vs concurrent chemotherapy and HDPRT (C-HDPRT) in patients with good performance status, locally advanced/small volume metastatic NSCLC not suitable for radical chemo-radiotherapy
  • ALTG 09/005 TROG 09.02 CHISEL: Phase III randomised trial of highly conformal hypofractionated image guided (“stereotactic”) radiotherapy vs conventionally fractionated radiotherapy for inoperable early stage I NSCLC